Close
Close
Treatment Database
4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
Trade Name not avaiable
Orphan Indication Angelman syndrome
USA Market Approval
USA Designation Date 06-09-2016
Sponsor Ovid Therapeutics
1460 Broadway
New York, New York, 10036
More about Angelman syndrome
Free Newsletter
Related Videos